摘要
目的:研究细胞质胸苷激酶1(TK1)在原发性肝癌(PHC)中的表达情况。方法:用免疫增强化学发光法与电化学发光法分别对33例PHC、38例肝硬化、36例肝炎和35例健康人的血清TK1、AFP水平进行检测。结果:PHC组TK1和AFP水平明显高于对照组、肝炎组、肝硬化组(P<0.05),PHC组TK1与AFP呈正相关(r=0.966,P<0.05),PHC组低分化患者TK1水平明显高于中/高分化患者,TNMⅢ+Ⅳ分期患者明显高于Ⅰ+Ⅱ分期患者,TK1≤2.0 pmol/L患者3年生存率和生存时间高于>2.0 pmol/L患者(P<0.05);TK1>2.0 pmol/L和TNM分期≥Ⅲ期是影响PHC患者总体生存率的独立危险因素。结论 :血清TK1可作为PHC诊断、疗效监测、预后评估的一项潜在指标。
Objective To investigate the expressions of TK1 （thymidine kinase 1） in PHC （primary hepatic carcinoma）. Methods TKI and AFP in serum of 33 cases of PHC （primary hepatic carcinoma）, 38 cases of hepatic cirrhosis, 36 cases of hepatitis and 35 cases of healthy people were detected by means of Western blot-enhanced chemiluminecence and electrochemiluminescence. Results The difference of TKI level in PHC group indicated significance when compared with that in hepatic cirrhosis group, hepatitis group and control group （U value was 436.4, 352.1, 163.6, respectively, all P 〈 0.01）. TK1 level in patients with PHC was related with differentiation （Х^2 = 7.476,P 〈 0.05） and TNM stage （Х^2 = 7.227,P 〈 0.05） ,but not with sex, age, tumor diameter, number of tumors, vascular invasion, lymph node metastasis （P 〉 0.05）. Kaplan- Meier curve analysis revealed that PHC patients with TK1 ≤2.0 pmol/L had a significantly shortened overall survival when compared with those with TK1 〉 2.0 pmol/L（Х^2 = 3.954,P 〈 0.05）. Mnhivariable Cox regression analysis indicated that the level of TK1 and TNM stage were the independent risk factors for patients with PHC （all P 〈0.05）. Conclusions The detection of TK1 has a certain clinical value in the diagnosis, monitoring and evaluation of the prognosis of the PHC.
出处
《实用医学杂志》
CAS
北大核心
2016年第3期396-399,共4页
The Journal of Practical Medicine
基金
江苏省连云港市卫生局科研项目(编号:1329)
关键词
原发性肝癌
细胞质胸苷激酶1
预后
Primary hepatic carcinoma
Thymidine kinase 1
Prognosis
